-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 23 News On June 21, the official website of the State Food and Drug Administration showed that Chengdu Better Pharmaceutical's metformin hydrochloride sustained-release tablets were approved for production of generic 4 types, which are deemed to have been reviewed
.
According to data from Meinenet, in 2020, the combined sales of metformin hydrochloride sustained-release tablets in China's public medical institutions and Chinese urban physical pharmacies will reach nearly 1.
8 billion yuan
.
At present, there are more than 40 manufacturers of this product.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Zhengda Tianqing Pharmaceutical Group have been reviewed
.
.
According to data from Meinenet, in 2020, the combined sales of metformin hydrochloride sustained-release tablets in China's public medical institutions and Chinese urban physical pharmacies will reach nearly 1.
8 billion yuan
.
At present, there are more than 40 manufacturers of this product.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Zhengda Tianqing Pharmaceutical Group have been reviewed
.
June 21, 2021, release of drug approval documents pending receipt
Data show that metformin is the first choice for the treatment of diabetic patients, and has the effects of lowering blood sugar and improving insulin resistance
.
The main dosage form marketed at home and abroad is tablets, and sustained-release tablets can significantly reduce gastrointestinal adverse reactions after taking the drug , and reduce the number of daily medications, from 2-3 times a day to once a day, thereby increasing Drug safety and compliance
.
.
The main dosage form marketed at home and abroad is tablets, and sustained-release tablets can significantly reduce gastrointestinal adverse reactions after taking the drug , and reduce the number of daily medications, from 2-3 times a day to once a day, thereby increasing Drug safety and compliance
.
Sales of Metformin Hydrochloride Sustained-Release Tablets in Chinese Public Medical Institutions and Chinese Urban Entity Pharmacies
Source: Mi Nei Net Database
According to data from Menet.
com, in 2020, the total sales of metformin hydrochloride sustained-release tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminal metformin hydrochloride sustained-release tablets will be nearly 1.
8 billion Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year increase of more than 20%
.
com, in 2020, the total sales of metformin hydrochloride sustained-release tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminal metformin hydrochloride sustained-release tablets will be nearly 1.
8 billion Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year increase of more than 20%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are more than 40 manufacturers of metformin hydrochloride sustained-release tablets.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group have been reviewed
.
At present, the supplementary applications for consistency evaluation of 5 companies including Chongqing Kerui Nanhai Pharmaceutical and Hainan Haili Pharmaceutical are under review and approval; 9 companies including Shandong New Times Pharmaceutical, Harbin Zhenbao Pharmaceutical, and Chenxin Pharmaceutical are reporting under the new classification.
The product is under review and approval, and will be deemed as over-evaluated after approval
.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group have been reviewed
.
At present, the supplementary applications for consistency evaluation of 5 companies including Chongqing Kerui Nanhai Pharmaceutical and Hainan Haili Pharmaceutical are under review and approval; 9 companies including Shandong New Times Pharmaceutical, Harbin Zhenbao Pharmaceutical, and Chenxin Pharmaceutical are reporting under the new classification.
The product is under review and approval, and will be deemed as over-evaluated after approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network, June 23 News On June 21, the official website of the State Food and Drug Administration showed that Chengdu Better Pharmaceutical's metformin hydrochloride sustained-release tablets were approved for production of generic 4 types, which are deemed to have been reviewed
.
According to data from Meinenet, in 2020, the combined sales of metformin hydrochloride sustained-release tablets in China's public medical institutions and Chinese urban physical pharmacies will reach nearly 1.
8 billion yuan
.
At present, there are more than 40 manufacturers of this product.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Zhengda Tianqing Pharmaceutical Group have been reviewed
.
.
According to data from Meinenet, in 2020, the combined sales of metformin hydrochloride sustained-release tablets in China's public medical institutions and Chinese urban physical pharmacies will reach nearly 1.
8 billion yuan
.
At present, there are more than 40 manufacturers of this product.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Zhengda Tianqing Pharmaceutical Group have been reviewed
.
June 21, 2021, release of drug approval documents pending receipt
Data show that metformin is the first choice for the treatment of diabetic patients, and has the effects of lowering blood sugar and improving insulin resistance
.
The main dosage form marketed at home and abroad is tablets, and sustained-release tablets can significantly reduce gastrointestinal adverse reactions after taking the drug , and reduce the number of daily medications, from 2-3 times a day to once a day, thereby increasing Drug safety and compliance
.
.
The main dosage form marketed at home and abroad is tablets, and sustained-release tablets can significantly reduce gastrointestinal adverse reactions after taking the drug , and reduce the number of daily medications, from 2-3 times a day to once a day, thereby increasing Drug safety and compliance
.
Sales of Metformin Hydrochloride Sustained-Release Tablets in Chinese Public Medical Institutions and Chinese Urban Entity Pharmacies
Source: Mi Nei Net Database
According to data from Menet.
com, in 2020, the total sales of metformin hydrochloride sustained-release tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminal metformin hydrochloride sustained-release tablets will be nearly 1.
8 billion Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year increase of more than 20%
.
com, in 2020, the total sales of metformin hydrochloride sustained-release tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminal metformin hydrochloride sustained-release tablets will be nearly 1.
8 billion Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year increase of more than 20%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are more than 40 manufacturers of metformin hydrochloride sustained-release tablets.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group have been reviewed
.
At present, the supplementary applications for consistency evaluation of 5 companies including Chongqing Kerui Nanhai Pharmaceutical and Hainan Haili Pharmaceutical are under review and approval; 9 companies including Shandong New Times Pharmaceutical, Harbin Zhenbao Pharmaceutical, and Chenxin Pharmaceutical are reporting under the new classification.
The product is under review and approval, and will be deemed as over-evaluated after approval
.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group have been reviewed
.
At present, the supplementary applications for consistency evaluation of 5 companies including Chongqing Kerui Nanhai Pharmaceutical and Hainan Haili Pharmaceutical are under review and approval; 9 companies including Shandong New Times Pharmaceutical, Harbin Zhenbao Pharmaceutical, and Chenxin Pharmaceutical are reporting under the new classification.
The product is under review and approval, and will be deemed as over-evaluated after approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network, June 23 News On June 21, the official website of the State Food and Drug Administration showed that Chengdu Better Pharmaceutical's metformin hydrochloride sustained-release tablets were approved for production of generic 4 types, which are deemed to have been reviewed
.
According to data from Meinenet, in 2020, the combined sales of metformin hydrochloride sustained-release tablets in China's public medical institutions and Chinese urban physical pharmacies will reach nearly 1.
8 billion yuan
.
At present, there are more than 40 manufacturers of this product.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Zhengda Tianqing Pharmaceutical Group have been reviewed
.
.
According to data from Meinenet, in 2020, the combined sales of metformin hydrochloride sustained-release tablets in China's public medical institutions and Chinese urban physical pharmacies will reach nearly 1.
8 billion yuan
.
At present, there are more than 40 manufacturers of this product.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Zhengda Tianqing Pharmaceutical Group have been reviewed
.
June 21, 2021, release of drug approval documents pending receipt
Data show that metformin is the first choice for the treatment of diabetic patients, and has the effects of lowering blood sugar and improving insulin resistance
.
The main dosage form marketed at home and abroad is tablets, and sustained-release tablets can significantly reduce gastrointestinal adverse reactions after taking the drug , and reduce the number of daily medications, from 2-3 times a day to once a day, thereby increasing Drug safety and compliance
.
Adverse reactions adverse reactions adverse reactions.
The main dosage form marketed at home and abroad is tablets, and sustained-release tablets can significantly reduce gastrointestinal adverse reactions after taking the drug , and reduce the number of daily medications, from 2-3 times a day to once a day, thereby increasing Drug safety and compliance
.
Sales of Metformin Hydrochloride Sustained-Release Tablets in Chinese Public Medical Institutions and Chinese Urban Entity Pharmacies
Source: Mi Nei Net Database
According to data from Menet.
com, in 2020, the total sales of metformin hydrochloride sustained-release tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminal metformin hydrochloride sustained-release tablets will be nearly 1.
8 billion Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year increase of more than 20%
.
Hospital hospital hospital pharmacy pharmacy pharmacycom, in 2020, the total sales of metformin hydrochloride sustained-release tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminal metformin hydrochloride sustained-release tablets will be nearly 1.
8 billion Among them, the terminal growth rate of public medical institutions in China is the fastest, with a year-on-year increase of more than 20%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are more than 40 manufacturers of metformin hydrochloride sustained-release tablets.
Among them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group have been reviewed
.
At present, the supplementary applications for consistency evaluation of 5 companies including Chongqing Kerui Nanhai Pharmaceutical and Hainan Haili Pharmaceutical are under review and approval; 9 companies including Shandong New Times Pharmaceutical, Harbin Zhenbao Pharmaceutical, and Chenxin Pharmaceutical are reporting under the new classification.
The product is under review and approval, and will be deemed as over-evaluated after approval
.
Enterprise business enterpriseAmong them, more than 20 companies such as Chengdu Hengrui Pharmaceutical, Yichang Renfu Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group have been reviewed
.
At present, the supplementary applications for consistency evaluation of 5 companies including Chongqing Kerui Nanhai Pharmaceutical and Hainan Haili Pharmaceutical are under review and approval; 9 companies including Shandong New Times Pharmaceutical, Harbin Zhenbao Pharmaceutical, and Chenxin Pharmaceutical are reporting under the new classification.
The product is under review and approval, and will be deemed as over-evaluated after approval
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
